惠泰醫療(688617.SH):2021年度淨利潤預增73.32%-88.67%
格隆匯1月27日丨惠泰醫療(688617.SH)公佈2021年年度業績預吿,經財務部門初步測算,預計2021年年度實現歸屬於母公司所有者的淨利潤為人民幣1.92億元至2.09億元,同比增加73.32%到88.67%;歸屬於母公司所有者的扣除非經常性損益的淨利潤為人民幣1.7億元至1.87億元,同比增加73.92%到91.31%。
本期業績變化的主要原因系:(一)報吿期內,公司圍繞戰略發展方向,穩步有序推進各項工作,積極發揮研發、技術、質量、產品、市場、渠道等多方面經營優勢,進一步加大新產品、新技術的研發投入,不斷加大市場開拓力度。公司電生理實現從二維到三維的佈局突破,血管介入類產品的覆蓋率及入院滲透率也進一步提升,國際業務持續較快發展,完成10餘個國家近50個產品註冊批件。報吿期內各產品線均較同期有不同程度增長,其中冠脈產品線較上年同期增長111%。(二)公司持續加強精益化生產管理,產能不斷釋放,規模效應帶來生產製造環節的降本增效,同時公司加強成本費用管控,盈利能力穩中有升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.